TELCON RF PHARMACEUTICAL (200230.KQ) Earnings Analysis

TELCON RF PHARMACEUTICAL (200230.KQ) has no confirmed upcoming earnings date. Trailing P/E -0.67.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 200230.KQ next report earnings?

No confirmed upcoming earnings date is currently scheduled for 200230.KQ. This page updates as the calendar is published.

200230.KQ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-091,437.8 KRWn/an/an/a
2025-11-12-138 KRWn/an/an/a
2025-08-18-149.64644 KRWn/an/an/a
2025-05-15-1,217.19492 KRWn/an/an/a
2025-03-11-1,015.20517 KRWn/an/an/a
2024-11-14250 KRWn/an/an/a
2024-08-14-84.52739 KRWn/an/an/a

200230.KQ valuation and analyst view

Trailing P/E-0.67
Trailing EPS-1,211.16777 KRW
Price / book0.15
Dividend yield0.00%
Market cap14.45B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is TELCON RF PHARMACEUTICAL (200230.KQ)'s next earnings date?

No confirmed upcoming earnings date is currently scheduled for 200230.KQ. This page updates as the calendar is published.

Did 200230.KQ beat earnings last quarter?

Consensus estimate data was not available for 200230.KQ's 2026-03-09 report.

What is 200230.KQ's current P/E ratio and EPS?

200230.KQ trades at a trailing P/E of -0.67 on trailing EPS of -1211.1677685342465 KRW.

What do analysts rate 200230.KQ?

200230.KQ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.